Dalargin (Dalargin)

Composition Pharmacodynamics Indications Carefully Contraindications Dosing and Administration Side effects Form release / dosage
Read on
Active substanceTyrosyl-D-alanyl-glycyl-phenylalanyl-leucyl-arginine diacetateTyrosyl-D-alanyl-glycyl-phenylalanyl-leucyl-arginine diacetate
Similar drugsTo uncover
  • Dalargin
    lyophilizate w / m in / in 
    FGBU RKNPK ROSZDRAVA - EPMPP     Russia
  • Dalargin-Deco
    lyophilizate w / m in / in 
    Company DEKO, LLC     Russia
  • Dalargin-Ellara®
    lyophilizate w / m in / in 
    ELLARA, LTD.     Russia
    • Dosage form: & nbsplyophilizate for the preparation of solution for intravenous and intramuscular administration
    Composition:Each ampoule contains 1 mg of tyrosyl-D-alanyl-glycyl-phenylalanyl-leucyl-arginine diacetate (dalargin).
    Description:White porous mass or amorphous powder. It is possible to smell acid acetic acid.
    Pharmacotherapeutic group:Peptic ulcer treatment - regulatory peptide
    ATX: & nbsp

    A.02.B.X   Other antiulcer drugs

    Pharmacodynamics:
    Dalargin is a synthetic hexapeptide, an analog of leucine-enkephalin. Promotes healing of stomach and duodenal ulcers. Has a moderate antisecretory activity, reduces the acidity of gastric juice.
    Dalargin suppresses the external secretion of the pancreas in response to various stimuli (food, secretin, etc.). With experimental damage to the pancreas, the drug reduces hyperfermentation, limits foci of necrosis and promotes their replacement with a full-length tissue,weaken the synthesis of proteolytic enzymes in acinar cells of the pancreas.
    Has a slight hypotensive effect.
    Indications:
    Applied with exacerbations of gastric ulcer and duodenal ulcer, acute pancreatitis, pancreatic necrosis.
    Contraindications:
    Hypersensitivity to the drug, arterial hypotension, acute infectious processes, phenylketonuria, pregnancy, lactation, children's age.
    Dosing and Administration:
    The drug is administered intravenously or intramuscularly. Immediately before use, the contents of the ampoule are dissolved in 1 ml of 0.9% sodium chloride solution.
    With exacerbations of peptic ulcer of the stomach and duodenum, a single dose of 1-2 mg, the highest daily - 5 mg. The course of treatment is 3-4 weeks. The total dose for the course of treatment is 30-50 mg.
    In acute pancreatitis, the drug is administered intravenously at a dose of 2 mg, then 5 mg 1 -2 times a day. The course of treatment 4-6 days.
    When pancreatic necrosis is administered intravenously 5 mg 3-4 times: a day (after 6-8 hours). The course of treatment is from 2 to 6 days.
    Side effects:
    Allergic reactions, lowering blood pressure.
    Special instructions:
    The safety of the drug in children and during breastfeeding is not established.
    Form release / dosage:Lyophilizate for the preparation of a solution for intravenous and intramuscular administration 1 mg.
    Packaging:
    Lyophilizate for the preparation of a solution for intravenous and intramuscular administration of 1 mg in ampoules of 1 ml, 2 ml. 5 ampoules in a contoured cell pack of a polyvinyl chloride film. 1 or 2 contour squares with instructions for medical use in a pack of cardboard.
    Storage conditions:
    List B. Store in a dry, dark place at a temperature of no higher than 20 ° C. Keep out of reach of children.
    Shelf life:5 years. Do not use after the expiration date printed on the package.
    Terms of leave from pharmacies:On prescription
    Registration number:P N001319 / 01
    Date of registration:23.12.2009 / 21.02.2014
    Expiration Date:Unlimited
    The owner of the registration certificate:FGBU RKNPK ROSZDRAVA - EPMPP FGBU RKNPK ROSZDRAVA - EPMPP Russia
    Manufacturer: & nbsp
    Information update date: & nbsp17.03.2017
    Illustrated instructions
      Instructions
      Up